0001209191-18-039732.txt : 20180627 0001209191-18-039732.hdr.sgml : 20180627 20180627200144 ACCESSION NUMBER: 0001209191-18-039732 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180625 FILED AS OF DATE: 20180627 DATE AS OF CHANGE: 20180627 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: SLATTERY JOSEPH P CENTRAL INDEX KEY: 0001246530 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-19437 FILM NUMBER: 18922939 MAIL ADDRESS: STREET 1: C/O TRANSENTERIX, INC. STREET 2: 635 DAVIS DRIVE, SUITE 300 CITY: MORRISVILLE STATE: NC ZIP: 27560 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: TRANSENTERIX INC. CENTRAL INDEX KEY: 0000876378 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 112962080 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 635 DAVIS DRIVE STREET 2: SUITE 300 CITY: MORRISVILLE STATE: NC ZIP: 27560 BUSINESS PHONE: 919-765-8400 MAIL ADDRESS: STREET 1: 635 DAVIS DRIVE STREET 2: SUITE 300 CITY: MORRISVILLE STATE: NC ZIP: 27560 FORMER COMPANY: FORMER CONFORMED NAME: SafeStitch Medical, Inc. DATE OF NAME CHANGE: 20080211 FORMER COMPANY: FORMER CONFORMED NAME: CELLULAR TECHNICAL SERVICES CO INC DATE OF NAME CHANGE: 19930328 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2018-06-25 0 0000876378 TRANSENTERIX INC. TRXC 0001246530 SLATTERY JOSEPH P C/O TRANSENTERIX, INC. 635 DAVIS DRIVE, SUITE 300 MORRISVILLE NC 27560 0 1 0 0 EVP and CFO Common Stock 2018-06-25 4 M 0 37875 1.53 A 201240 D Common Stock 2018-06-25 4 M 0 64583 2.45 A 265823 D Common Stock 2018-06-25 4 M 0 131383 2.94 A 397206 D Common Stock 2018-06-25 4 S 0 233841 5.00 D 163365 D Common Stock 2018-06-26 4 M 0 93616 2.94 A 256981 D Common Stock 2018-06-26 4 M 0 8465 3.82 A 265446 D Common Stock 2018-06-26 4 S 0 178598 5.00 D 86848 D Common Stock 2018-06-26 4 S 0 4483 5.01 D 82365 D Common Stock 2018-06-27 4 S 0 82365 6.01 D 0 D Common Stock 2018-06-27 4 M 0 184035 3.82 A 184035 D Common Stock 2018-06-27 4 M 0 16164 3.94 A 200199 D Common Stock 2018-06-27 4 S 0 200199 6.00 D 0 D Common Stock 25000 I By IRA Stock Option 1.53 2018-06-25 4 M 0 37875 0.00 D 2026-10-25 Common Stock 37875 87500 D Stock Option 2.45 2018-06-25 4 M 0 64583 0.00 D 2025-10-28 Common Stock 64583 35417 D Stock Option 2.94 2018-06-25 4 M 0 131383 0.00 D 2025-02-04 Common Stock 131383 138617 D Stock Option 2.94 2018-06-26 4 M 0 93616 0.00 D 2025-02-04 Common Stock 93616 45001 D Stock Option 3.82 2018-06-26 4 M 0 8465 0.00 D 2026-02-12 Common Stock 8465 321535 D Stock Option 3.82 2018-06-27 4 M 0 184035 0.00 D 2026-02-12 Common Stock 184035 137500 D Stock Option 3.94 2018-06-27 4 M 0 16164 0.00 D 2024-05-27 Common Stock 16164 9736 D The transaction occurred pursuant to a written trading plan dated November 29, 2017 meeting the requirements of Rule 10b5-1(c). The sale price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.01 to $6.025 inclusive. The reporting person undertakes to provide to TransEnterix, Inc., any security holder of TransEnterix, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Following the sales on June 25, 2018, June 26, 2018 and June 27, 2018, the reporting person continues to beneficially own 25,000 shares of the company's common stock. The reporting person also holds stock options to acquire 1,886,821 shares of common stock, of which approximately 27% are vested, and restricted stock units representing an additional 762,444 shares of common stock subject to forfeiture restrictions. The sale price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.00 to $6.01 inclusive. The reporting person undertakes to provide to TransEnterix, Inc., any security holder of TransEnterix, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. Vests 25% on the first anniversary of the date of grant and 1/48th of the entire award monthly on the vesting date anniversary for 36 months, subject to acceleration as set forth in the Incentive Plan and in connection with a termination of employment following a change in control under an employment agreement. /s/ Joshua Weingard, as Attorney-in-Fact for Joseph Slattery 2018-06-27